Seeking Alpha

poker player fos

poker player fos
Send Message
View as an RSS Feed
View poker player fos' Comments BY TICKER:
Latest  |  Highest rated
  • Shell (RDS.A) may have taken the lead - at least in the rumor mill - as the bidder most likely to succeed in winning a share of InterOil’s (IOC) LNG project in Papua New Guinea, Platts reports. Shell’s perceived advantage over Exxon (XOM) and Total (TOT) centers on its existing relationship with the PNG government, strengthened by its ownership of emerging floating LNG technology. [View news story]
    Still think its Exxon. But its great to have three potential majors bidding up the price. This is going to play out nicely - soon guys like Adam who have been publicly telling you to short IOC since the 30s will once again be proven wrong. The manipulation stops shortly
    May 3 01:40 AM | Likes Like |Link to Comment
  • InterOil: The $3.5 Billion Penny Stock [View article]
    Sorry Omer, this is not just a guy presenting the short case. He has zero energy background and as such presents no real case on the energy side to short IOC. He carefully crafts things with no basis like "management is crooked" without discussing 1) the fact that he has no energy background 2) that he was so wrong and the stock ran from the 30's to the 90s since he started recommending shorting IOC and now at nearly double his first short IOC call he tells you to short again but conveniently fails to disclose that he was so wrong previously. 3) His articles are again filled with innuendo and negative spin and no real new facts. One of his articles was completely proven inaccurate but a respected energy analyst who was so upset with the distorted nature of the accusations he actually put a report out disputing the points. This stock has a history of short hedge funds getting negative stories published on PNG blogs and such, had one large IOC short fund hire know felon Barry Minkow (security fraud) to make accusations similar to those that Adam makes - minkow is again in jail. No this is not a balanced short thesis article - its a "IOC is running lets knock it down" thesis
    Apr 16 10:16 AM | 3 Likes Like |Link to Comment
  • InterOil: The $3.5 Billion Penny Stock [View article]
    Its important to understand that Adam has HORRIBLE IOC past calls going back to 2011 Who could forget when his call to short in the high 30's was literally the gun to sound the bottom. Same with today. He is an ex poker player again telling you to short a stock at $70 that he previously told you to short in the high $30s/low $40s in the article below. Its a fact his past IOC articles preceded runs all the way up to mid 90s. So now he tries again almost at a double from where he said IOC was overvalued in this article (which was the second in two days he recommended shorting IOC in the high 30s/low 40s). Stock went to mid 90's. Its also important to see that Adam used to be a poker player and has little finance background. All of these must be disclosed before reading this article:

    http://seekingalpha.co...
    Apr 16 01:55 AM | 2 Likes Like |Link to Comment
  • InterOil: The $3.5 Billion Penny Stock [View article]
    How you can call the IOC management "crooked" and be allowed to be published is a head scratcher, especially since you have been telling people to short IOC since Nov 2011 when the stock was in the 30's and then ran to the 90s. Who is crooked are the hedge funds that short IOC and manipulate the trading by hiding over 80% of the volume of this NYSE company in dark pools, and then get articles in the PNG press, hire known felons like Barry Minkow to publish questionable articles (Minkow is back in jail after being hired by a famous IOC short hedge fund). As an ex poker player with NO energy or finance background - it really is amazing how many articles you get published.
    Apr 15 08:42 PM | 5 Likes Like |Link to Comment
  • New Evidence Questions Whether InterOil Actually Received A Bid From A Supermajor For Its Asset Selldown [View article]
    Its important to understand that Adam has HORRIBLE IOC past calls going back to 2011 Who could forget when his call to short in the high 30's was literally the gun to sound the bottom. Same with today. He is an ex poker player again telling you to short a stock at $70 that he previously told you to short in the high $30s/low $40s in the article below. Its a fact his past IOC articles preceded runs all the way up to mid 90s. So now he tries again almost at a double from where he said IOC was overvalued in this article (which was the second in two days he recommended shorting IOC in the high 30s/low 40s). Stock went to mid 90's. Its also important to see that Adam used to be a poker player and has little finance background. All of these must be disclosed before reading this article

    http://seekingalpha.co...
    Apr 9 09:59 AM | 4 Likes Like |Link to Comment
  • AP Pharma And Ziopharm: The Differences Between Bad News [View article]
    Follow RJ Kirk - he has made money for me at New River, Clinical Data and Scios. Intrexon IPO as many are posting elsewhere - is more important to ZIOP then people think. Biothoughts has made me a lot of money with his biotech recommendations
    Apr 1 04:04 AM | 1 Like Like |Link to Comment
  • Was InterOil's Chairman Engaged In A Conflict Of Interest With Calvin College And The Fuller Fund? [View article]
    Westlake note responding to these accusations

    There are accusations in the market place which suggest that members of the board and management of InterOil Corporation
    (InterOil, IOC, or the Company) acted improperly related to transactions in shares of the Company and related entities. We assume our clients are familiar with these accusations.
    • We have done some additional research of the public filings from the nonprofit mentioned, interviewed management and reviewed
    the early InterOil filings related to ownership interest.
    • We do not believe there were improper actions by IOC management or board members and maintain our BUY
    recommendation and $115 Price Target.
    o We understand the Fuller Foundation (Foundation) ownership in IOC was from its original investment as part of a group
    to purchase the refinery in Alaska, which was refurbished and moved to Papua New Guinea to form the original core of
    InterOil. This led to the Fuller Foundation receiving a significant position in IOC that was held in a US entity, which was
    necessary to secure the debt financing from the Overseas Private Investment Corp (OPIC).
    o We understand from multiple independent sources that the Foundation did not purchase interests in IOC from any of the
    Company officers or directors. We understand that the Foundation did not purchase any IOC shares or related instruments
    in its client accounts or investment funds. The Foundation was audited by Deloitte and Touche during the years that we
    reviewed, and we believe this firm would have reviewed for conflicts of interests and ensured appropriate policies were in place.
    o The budgetary issues at Calvin College are similar to issues at many other college endowments: (NY Times, Moody’s).
    o Mr. Samuel Delcamp is a recent addition to the InterOil Board and was previously the Executive Director of the Fuller
    Foundation. His average total compensation for 2001-2011 of ~$536,000/yr is inline with our expectations for somebody
    heading a foundation managing ~$450MM and living in a high cost area such as southern California. For reference, media
    reports put the compensation of the ~$2 billion University of North Carolina endowment CEO at ~$665,000 in 2006 (link).
    o The recently published summary report from Calvin College indicates that the primary issues related to building new
    infrastructure in anticipation of additional gifts and investment returns (link). Both gifts and investment returns
    underperformed expectations during the recent recession. Given Calvin College’s location in Michigan, we suspect industries
    supporting its alumni were particularly hard hit.

    • We believe this story has been an overhang on the stock for some time. We originally saw a similar story on March 22
    . We began reviewing the public filings and were able to engage with management on March 25 about the potential issues. Management has
    been diligent in responding to our questions with written correspondence that clarifies many of the issues.
    • We are working to communicate directly with Calvin College, but they seem overwhelmed by the recent influx of calls.
    • Please refer to our initiation piece on March 13, 2013 for more discussion of the Company, our investment thesis, and risks
    Mar 29 05:51 AM | 2 Likes Like |Link to Comment
  • Was InterOil's Chairman Engaged In A Conflict Of Interest With Calvin College And The Fuller Fund? [View article]
    This former poker player told you to short IOC in the 30s in November 2011 and it proceeded to rise $50+ afterwards. He again had a short article recently and the stock went higher. Its only fair disclosure to warn people his track record on this stock is not very good.
    Mar 27 01:35 AM | 2 Likes Like |Link to Comment
  • There's Something Not Quite Right About InterOil [View article]
    An Adam G IOC article in the past has had the initial negative effect on share price like in Nov 11 and thereafter but history shows if you review the IOC articles, that initial dip from the negative headline almost always results in a rebound to new highs. This will be no different.
    Read the Nov 11 Adam IOC slam piece when he told us to short inthe 30s. Its only fair to disclose that the stock did not go down from there but ran to all time high mid 90s. And he posted 2 negative IOC articles in two days then. Many of the items above were included in that article before the $50+ run in the stock after the article. Important disclosure
    Mar 20 06:44 PM | 1 Like Like |Link to Comment
  • There's Something Not Quite Right About InterOil [View article]
    Its important to understand that Adam has HORRIBLE IOC past calls going back to 2011 Who could forget when his call to short in the high 30's was literally the gun to sound the bottom. Same with today. He is an ex poker player again telling you to short a stock at $70 that he previously told you to short in the high $30s/low $40s in the article below. Its a fact his past IOC articles preceded runs all the way up to mid 90s. So now he tries again almost at a double from where he said IOC was overvalued in this article (which was the second in two days he recommended shorting IOC in the high 30s/low 40s. Stock went to mid 90's.

    http://seekingalpha.co...


    Mar 20 09:28 AM | 4 Likes Like |Link to Comment
  • There's Something Not Quite Right About InterOil [View article]
    Just to be fair - its important that Adam recommended going short IOC in the 40's in the article below before it ran to the 90's. He is repeating much of the same that he did back then in this seeking article:

    http://seekingalpha.co...
    Mar 20 09:07 AM | 5 Likes Like |Link to Comment
  • Does Celgene Have More Room To Run In 2013? [View article]
    TWO more clear items came out since the close yesterday that again proves CELG guidance conservative. Guidance for this yr and through 2017 is based on STABLE share count. Even though CELG has bought back $5 billion of stock over the past few yrs. Today they announced they have already bought $385 million of stock back so far this yr - in a month & a half and even more importantly will by $600 million back directly from an investment bank as allowed in their buyback agreement. Pretty clear CELG will buyback about $1 billion in the first half vs stable share count in ests. Will help EPS nicely, One analyst ests that the 2017 $13 to $14 EPS guidance based on stable share count is really $15 - $16 if you include regular buybacks. They will happen - by 2017 CELG cash flow after ALL EXPENSES will be over $5 billion a yr. This stock is VASTLY undervalued and should be trading at a PREMIUM PEG to other large bios with slower growth like BIIB, AMGN and GILD. the 0.76 PEG vs 1.30 BIIB is a joke. The 0.4 PEG on now VERY conservative 2016 #'s means you get the best EPS growth in all of biotech and most of the S&P 500 at more than half off. Can't last - CELG is going higher.

    Also JP Morgan based on checks say Pomalyst launch will be much better - quicker than expected. As author says - Pomalyst is strongest MM drug ever approved working when patient even fails Revlimid, Velcade and stem cell transplants so this should not be a surprise. JP Morgan raises ests last night in this report:

    http://bit.ly/YGNIZu
    Feb 20 02:47 PM | Likes Like |Link to Comment
  • Has InterOil Turned Into A Full-Blown Scam? [View article]
    It was Nov 14th 2011 and Nov 15th 2011that this author Adam G posted to IOC articles recommending shorting at lows that day of $42.52 and $39.66 - the stock went to the mid - 90s.

    Do the opposite - here is the link to one article:

    http://seekingalpha.co...
    Feb 19 11:03 PM | Likes Like |Link to Comment
  • Richard Pearson Responds On Ziopharm [View article]
    Very good comments on why the delay is good and why after they keep it down for a few days ziop should perform well:

    http://yhoo.it/TUmVbL
    Nov 16 01:20 PM | 1 Like Like |Link to Comment
  • Richard Pearson Responds On Ziopharm [View article]
    This is very good news imo. Quotes from analysts:

    o JP Morgan - "Picasso3 did pass the IDMC’s interim futility analysis" (this means they are seeing Pali efficacy or it would have been halted for futility).

    "ZIOP remains confident in the PFS performance of the control arm--is relatively confident this should not be the case given the data recently presented at ESMO for ifosfamide (a pro-drug for palifosfamide)" - Dox has been tested and retested and the control arm is not suddenly going to be the reason the trial is lasting longer especially since Dox is in both arms. - I bet its Pali-Dox. This is great news as we only need to get to the Votrient approved endpoint 2 months PFS.

    " We continue to see a relatively high probability of Phase 3 success for palifosfamide in first-line metastatic STS. Reiterate $8 target and Outperform"

    o Brinson Patrick: "Picasso Delay a Positive. Use current volatility/price as an attractive entry point. Outperform"

    We View the PICASSO 3 Delay as Positive News

    ZIOPHARM Oncology Inc. (ZIOP) yesterday announced that, after an analysis of progression-free survival (PFS) events by the Independent Data Monitoring Committee (IDMC) the palifosfamide PICASSO 3 trial in frontline metastatic soft tissue sarcoma (mSTS), the projected timing for the triggering event and announcement of top-line PFS results has been delayed from this quarter to the end of 1Q13. We believe the anticipated analysis of PFS in PICASSO 3 will be in favor of the palifosfamide treatment arm. With the shares currently at the lower end of values derived from our valuation analysis, we believe significant upside exists and reiterate our Market Outperform rating and 12-month price target of $7.

    We View the Delay as Positive News PICASSO 3 is designed with 85% power to detect a 0.60 hazard ratio (HR) ratio PFS advantage with palifosfamide. The company designated PFS as the primary endpoint for accelerated approval, and designated overall survival (OS) as the endpoint for full approval. The update on the trigger event’s delay likely also delays the timing of top-line OS data release, and thus may be viewed by some investors as negative news. We had believed the timing of top-line PFS data release this quarter as aggressive and only modeled modest sales of Palifosfamide in 2014 ($12.9MM), with the expectation for 3Q14 accelerated approval and full approval gained in 2015. As the IDMC recommended that PICASSO 3 proceed as designed and conducted with no changes, we remain confident that PICASSO 3 will demonstrate a PFS benefit with palifosfamide.

    We Recommend Using Share Volatility as an Entry Point The announcement of top-line PICASSO 3 PFS results is a binary event that we anticipate will be a key positive share driver. We recommend taking advantage of recently increased volatility (peaking up 177% since July) in ZIOP shares, and use current prices as an entry point for new positions.


    o JMP Securities
    "IDMC review affirms that trial is non-futile. our confidence in a successful outcome remains unchanged; reiterate Market Outperform rating and $10 price target for ZIOPHARM"
    Nov 16 12:25 PM | 1 Like Like |Link to Comment
COMMENTS STATS
32 Comments
57 Likes